Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3927MR)

This product GTTS-WQ3927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3927MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1957MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14436MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ9346MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11467MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ5002MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ1131MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ2441MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ3908MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW